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Abstract
The epidermal growth factor receptor (EGFR) is ex-
pressed in a variety of human solid tumors, including
malignant mesothelioma. EGFR has been implicated in
regulation of cell proliferation, survival, angiogenesis,
and metastasis, making it an ideal target for drug
development. ZD1839 (gefitinib) and OSI-774 (erlotinib)
are new, low-molecular-weight, EGFR-selective tyro-
sine kinase (TK) inhibitors, whereas CI-1033 is a pan-
EGFR family TK inhibitor. In the present study, we
used ZD1839, OSI-774, and CI-1033 and investigated
the effect of these drugs on proliferation, migration,
and matrix metalloprotease (MMP) production in three
malignant mesothelioma cell lines (M14K, ZL34, and
SPC212). Using [3H]thymidine incorporation, DNA syn-
thesis assay, we found that all three drugs inhibited
transforming growth factor-alpha (TGF-A)– induced
cellular proliferation in a dose-dependent manner. In
addition, all three drugs induced apoptosis in ZL34
cells as determined by flow cytometry using annexin-V
staining. Furthermore, all three drugs inhibited TGF-
A–induced cell migration (chemotaxis) in a dose-
dependent manner as determined by Boyden chamber
assay. TGF-A–induced MMP-9 production was also
inhibited in a dose-dependent manner as determined
by gelatin zymography in three cell lines tested. In
conclusion, our study demonstrates inhibitory ef-
fectiveness of EGFR-TK inhibitors in malignant
mesothelioma cells and suggests that these drugs
may be an effective treatment strategy for malignant
mesothelioma.
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Introduction
Malignant mesothelioma is a highly aggressive tumor,
which arises from mesothelial-lined surfaces, most often
the pleural cavities, but also from the peritoneum, peri-
cardium, and paratesticular soft tissues [1]. Malignant
mesotheliomas spread through the underlying basement
membrane or along serosal surfaces. Typically, mesothe-
lioma spreads to the pericardium, contralateral hemithorax,
and/or peritoneal cavity by invasion through the diaphragm.
Invasion through needle biopsy tracts and incisions in the
thoracic wall are common features in malignant mesothelioma
[6,7]. The resulting tumor often forms diffuse thickening of
involved surfaces rather than solitary rounded lesions seen in
other neoplasms. Metastases occur in up to 75% of mesothe-
lioma patients [31]. Three histologic subtypes of malignant
mesothelioma are distinguished: epithelial, fibrous (sarcoma-
toid), and mixed (biphasic). There is no effective standard
therapy for malignant mesothelioma regardless of the treat-
ment modality used. Although various chemotherapies have
been evaluated in malignant mesothelioma, few have shown
response rates better than 20% [3]. Notably, these therapies
did not prolong patient survival. Therefore, more effective
chemotherapy agents are needed.
The epidermal growth factor receptor (EGFR)2 is a trans-
membrane glycoprotein (Mr 170 kDa) with an external binding
domain and an intracellular tyrosine kinase (TK) domain. The
binding of EGFR ligands, such as transforming growth factor-
alpha (TGF-a), to EGFR induces receptor dimerization, fol-
lowed by activation of the intrinsic TK, leading to receptor
tyrosine autophosphorylation [35,38]. Activation of EGFR-TK
has been identified as an important feature that initiates the
cascade of intracellular signaling events that regulate cell
proliferation, survival, angiogenesis, cell movement, and me-
tastasis [14,45]. The EGFR is expressed in a variety of human
solid tumors, including malignant mesothelioma [15], and is
associated with disease progression, poor survival, and poor
response to traditional cytostatic therapy [17,18,33,43].
A previous study suggested that EGFR might be involved
in asbestos-induced pathogenesis of malignant mesothelioma
[46]. In addition, our previous study has also shown that EGFR
is functionally active and that ligation of this receptor induces
Abbreviations: EGFR, epidermal growth factor receptor; TGF-a, transforming growth factor-a;
TK, tyrosine kinase; MMPs, matrix metalloproteases; FCS, fetal calf serum; BSA, bovine
serum albumin; PI, propidium iodide; ECM, extracellular matrix
Address all correspondence to: Zhiwen Liu, Department of Clinical Immunology, F79, Hud-
dinge University Hospital, SE-141 86, Stockholm, Sweden. E-mail: zhiwen.liu@labmed.ki.se
1This work was supported by grants to J. Klominek from the Swedish Cancer Society and the
Swedish Heart and Lung foundation.
Received 5 April 2004; Revised 13 May 2004; Accepted 24 May 2004.
Copyright D 2004 Neoplasia Press, Inc. All rights reserved 1522-8002/04/$25.00
DOI 10.1593/neo.04271
Neoplasia . Vol. 6, No. 6, November/December 2004, pp. 705 – 712 705
www.neoplasia.com
RESEARCH ARTICLE
mesothelioma cell migration and matrix metalloprotease
(MMP)-9 production [29]. For these reasons, the blockade
of EGFR-activating pathway may provide a potential thera-
peutic target for treatment of malignant mesothelioma.
ZD1839 (gefitinib) and OSI-774 (erlotinib) are low-molec-
ular-weight EGFR-selective TK inhibitors, whereas CI-1033
is a pan-EGFR family TK inhibitor that blocks signal trans-
duction pathway implicated in cancer cell proliferation, sur-
vival, and other host-dependent processes promoting cancer
progression [5,19,41]. ZD1839, OSI-774, and CI-1033 are
currently under evaluation in clinical trials in patients with
lung cancer and other tumors.
In the present study, we examined if these three TK
inhibitors affect cell proliferation, cell migration, and MMP
production, and induce apoptosis in three established ma-
lignant mesothelioma cell lines representing different histo-
logic subtypes of this tumor.
Materials and Methods
Cells
Three human malignant mesothelioma cell lines were
used: M14K (epithelial type), ZL34 (fibrous type), and
SPC212 (mixed type) [37,39]. All malignant mesothelioma
cell lines were cultured in RPMI 1640 supplemented with 5%
fetal calf serum (FCS), penicillin (100 U/ml), streptomycin
(100 mg/ml), and 2 mM L-glutamine. The cells were main-
tained in a humidified atmosphere of 5% CO2 in air at 37jC.
Chemicals
ZD1839 was provided by AstraZeneca (Macclesfield,
UK). OSI-774 was provided by OSI/Genentech (Melville,
NY) and CI-1033 was provided by Pfizer (New York, NY).
All drugs were dissolved in dimethyl sulfoxide (DMSO) and
stored at 20jC. TGF-a was purchased from R&D Systems
(Abingdon, UK). RPMI 1640, FCS, penicillin, streptomycin,
and L-glutamine were obtained from Life Technologies
(Paisley, UK). Gelatin, BSA, and collagen type IV were
purchased from Sigma (St. Louis, MO).
RNA Isolation, cDNA Synthesis, Primers, and RT-PCR
Total RNA was isolated from cell lines using the guanidi-
nium isothiocyanate method as previously described [11].
cDNA synthesis was performed using a first-strand cDNA
synthesis kit (Pharmacia Biotech, Uppsala, Sweden) accord-
ing to the manufacturer’s instructions. For cDNA synthesis,
5 mg of total RNA were taken and Not- (T) 18 primers
were used for cDNA generation. The reverse transcript
(1 ml in a final volume of 25 ml) was subjected to PCR. The
primers used and the PCR procedures have been described
previously [42].
Reverse transcription-polymerase chain reaction (RT-PCR)
was performed on RNA samples from three malignant me-
sothelioma cell lines and a MCF-7 cell line (positive control)
[13]. PCR products were visualized by ethidium bromide
staining of 1% agarose gels. Integrity of RNA and cDNA
synthesis was monitored by amplification of b-actin mRNA.
Growth-Inhibition Assay
[3H]Thymidine incorporation assays were performed in
triplicate in 96-well microtiter plates. Each well was filled with
malignant mesothelioma cells (2  104) in serum-containing
medium. After 24 hours, the medium was changed and the
cells were cultured for additional 6 hours in serum-free
medium. Finally, fresh serum-free medium with indicated
concentrations of different drugs and/or TGF-a were added,
and the cells incubated for 48 hours. Control wells were filled
with serum-free medium. [3H]Thymidine (1 mCi/well) (Amer-
sham Life Science, Uppsala, Sweden) was added during the
last 18 hours of culture. The cells were harvested onto filters
with a plate harvester (Harvester 996; Tomtec, Hamden, CT)
according to the manufacture’s instructions and counted in
an automated counter (1450 MicroBeta Trilux; Wallac, Swe-
den AB, Stockholm, Sweden); results were expressed as
counts per minute (cpm).
In addition, growth-inhibition assays were also per-
formed by counting the number of viable cells after differ-
ent treatments.
Flow Cytometric Analysis of Apoptosis
To investigate whether different drugs induce apoptosis in
mesothelioma cells, flow cytometry was performed using a
FACScan analyzer after staining with annexin-V fluorescein
isothiocyanate (FITC) and propidium iodide (PI). The meso-
thelioma cells were cultured in six-well culture plates in the
presence of different drugs and/or TGF-a. After 24 hours
treatment, the cells were examined for phosphatidylserine
expression on the cell surface with the Annexin-V FITC
apoptosis detection kit (BioSource Europe´, S.A., Nivelles,
Belgium) according to the manufacturer’s instructions. The
cells that stained positive for annexin-V and negative for PI
were defined as in the early apoptosis.
Cell Migration Assay
The migration of mesothelioma cells was assayed using
48-well Boyden chambers (Neuro Probe, Cabin John, MD)
[8] fitted with 12-mm polyvinylpyrrolidone-free polycarbonate
filters (Poretics, Livermore, CA). For haptotaxis assays,
the lower side of filters were coated overnight at 4jC with
10 mg/ml of collagen type IV [25]. For determination of
chemotaxis, the filters were coated on both sides with
10 mg/ml of collagen type IV and the indicated concentrations
of TGF-a diluted in RPMI 1640 containing 1 mg/ml of BSA
were placed in the lower compartments of Boyden cham-
bers. Mesothelioma cells (5  104 cells, preincubated over-
night with the indicated concentrations of different drugs
and remained with the cells throughout the assay) were
placed in the upper compartments of Boyden chambers
and incubated for 5 hours in a humidified incubator at
37jC. At the end of the assays, the filters were removed,
fixed in methanol, and stained with Giemsa stain. The filters
were then placed onto glass slides and the cell pellets
corresponding to the upper wells were wiped off with cotton
swabs. Cells that have migrated through the pores to the
lower side of the filters were counted in a blinded fashion
using light microscopy under high-power field (400). For
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each triplicate, the number of cells in three high-power fields
was counted and the average was determined.
Gelatin Zymography
For determination of MMP production, mesothelioma
cells were cultured until subconfluent, serum-supplemented
medium was removed, and the cell monolayer was exten-
sively washed with PBS to remove remaining serum pro-
teins. The cells were then cultured in serum-free RPMI 1640
for 6 hours. TGF-a and/or different drugs were then added
and the cells were cultured for 36 hours. Aliquots of serum-
free conditioned medium (adjusted to the same number of
cells) were solubilized in sample buffer containing 2% sodi-
um dodecyl sulfate (SDS) without reducing agents, then the
samples were applied without boiling on 6% polyacrylamide
gels containing 2 mg/ml of gelatin. After electrophoresis, the
gels were washed in Hanks’ balanced salt solution (HBSS) in
the presence of 2.5% Triton X-100 for 2  20 minutes to
remove SDS, then briefly rinsed in HBSS. The gels were
then incubated in buffer (20 mM glycine, 10 mM CaCl2, and
1 mM ZnCl2, pH 8.3) for 48 hours at 37jC. After incubation,
the gels were stained in 0.1% Coomassie brilliant blue for
1 hour and destained. The substrate degrading enzymes
were identified as clear bands in the blue background. The
area and intensity of the bands was quantified by NIH Image
V.1.62 software (National Institutes of Health, Bethesda,
MD).
Results
Expression of EGFR in Mesothelioma Cells by RT-PCR
To characterize EGFR expressed by mesothelioma cells,
RT-PCR with specific primers was performed. As shown in
Figure 1, all three mesothelioma cell lines expressed EGFR.
Effect of TK Inhibitors on Proliferation of Mesothelioma Cells
To determine the effect of different drugs on proliferation
in mesothelioma cells, we performed DNA synthesis assay
using [3H]thymidine incorporation. Cell counts after incuba-
tion of mesothelioma cells with TGF-a and TK inhibitors were
also performed.
First, we investigated the effect of ZD1839, OSI-774, and
CI-1033 on cell proliferation at 24, 48, and 72 hours, respec-
tively. All three drugs inhibited TGF-a– induced cellular
proliferation in a time-dependent manner, reaching maxi-
mum inhibitory effect at 48 hours compared with controls
cultured without TK inhibitors (data not shown). We then
investigated the effect of different concentrations of TK
inhibitors on cell proliferation after 48 hours of incubation.
As shown in Figure 2 (A–C), three drugs inhibited cellular
proliferation in a dose-dependent manner and had significant
inhibitory effect at 10 mM concentration. In addition, three
drugs inhibited cellular proliferation at 10 mM concentration in
three mesothelioma cell lines as determined by cell counting
(data not shown).
Induction of Apoptosis by TK Inhibitors in Mesothelioma
Cells
To determine whether ZD1839-, OSI-774-, and CI-1033-
inhibited cellular proliferation was accompanied by apoptosis
in mesothelioma cells, we performed flow cytometric analy-
sis of mesothelioma cells after annexin-V and PI staining for
the detection of the early stage of apoptosis.
As shown in Figure 3, early stage of apoptosis was ob-
served in 14%, 28%, and 30% of the ZL34 cells treated with
10 mM ZD1839, OSI-774, and CI-1033, respectively. Howev-
er, all three drugs failed to induce apoptosis in the other
two mesothelioma cell lines (M14K and SPC212) (data not
shown).
Inhibition of TGF-a–Induced Chemotaxis by TK Inhibitors
To determine whether ZD1839, OSI-774, and CI-1033
inhibited migration of mesothelioma cells, we performed the
Boyden chamber assay. Two different assays were per-
formed: chemotaxis, using TGF-a as chemoattractant, and
haptotaxis, where the lower side of the filter was coated with
collagen type IV [25].
As shown in Figure 4 (A–C), TK inhibitors inhibited
TGF-a–induced cell migration in a dose-dependent manner
in three investigated mesothelioma cell lines. In contrast, the
same drugs failed to inhibit collagen type IV–induced hap-
totaxis, indicating that TK inhibitors act specifically on TGF-
a–induced motile events but not collagen type IV–induced
haptotaxis (data not shown).
Inhibition of MMP-9 Production by TK Inhibitors in Meso-
thelioma Cells
To determine whether different drugs inhibited TGF-a–
induced production of MMPs, we performed gelatin zymog-
raphy and quantified the production of MMPs by using
densitometry.
Aliquots of serum-free conditioned medium from meso-
thelioma cells treated with TGF-a in the presence or absence
of TK inhibitors were subjected to SDS-polyacrylamide gel
electrophoresis (PAGE) gelatin zymography. As shown in
Figure 5 (A–C), all three drugs inhibited the production of
Figure 1. Expression of EGFR in human malignant mesothelioma cells. Total
RNA from each sample was reverse-transcribed, amplified for 30 cycles, and
analyzed on 1.5% agarose gel. The 221- and 320-bp DNA fragments were
produced using primers designed to amplify EGFR and -actin cDNA
sequences, respectively. Positive control was MCF-7 for EGFR. The bands
were visualized using UV light and photographed.
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MMP-9 induced by TGF-a in a dose-dependent manner in
the three investigated mesothelioma cell lines. In contrast,
the level of MMP-2 production was not affected by the
same drugs. Notably, stable levels of MMP-2 can be viewed
as an internal control for loading of equal amounts of protein.
The human fibrosarcoma cell line HT-1080 was used as
positive control for demonstration of MMP-9 and MMP-2
production [9].
Discussion
Inhibition of EGFR signaling represents a promising
new strategy in the development of selective anticancer
Figure 2. (A–C) DNA synthesis assay. DNA synthesis was determined by incorporation of [3H]thymidine into mesothelioma cells. Different drugs (A, ZD1839; B,
OSI-774; C, CI-1033) and/or TGF-a (12.5 ng/ml) were added and cells incubated for 48 hours. The results are expressed as counts per minute (cpm) and
presented as the mean ± SD triplicates for each TGF-a and/or drug concentrations.
Figure 3. Induction of early-stage apoptosis by TK inhibitors in malignant mesothelioma cells. The apoptosis was determined by Annexin-V FITC and PI staining
and analyzed by flow cytometry. Histograms of cells versus log fluorescence intensity were generated. Shaded histograms represent fluorescence of cells treated
with TGF-a only; open histograms indicate fluorescence of cells treated with different drugs and TGF-a. The early stage of apoptosis was observed in 14%, 28%,
and 30% of the ZL34 cells treated with 10 M of ZD1839, OSI-774, and CI-1033, respectively. Data shown are representative of three independent experiments.
For each sample, 10,000 cells were analyzed.
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therapies. ZD1839 and OSI-774 are selective EGFR-TK
inhibitors, whereas CI-1033 is a pan-EGFR family TK inhib-
itor. In the present study, we evaluated the effect of these
three TK inhibitors on cell proliferation, induction of apopto-
sis, cell migration, and production of MMPs in cell lines
representing all three histologic subtypes of malignant
mesothelioma.
Exposure of mesothelioma cells to TK inhibitors produced
a dose-dependent growth inhibition in all cell lines tested.
Although previous studies have shown that TK inhibitors may
induce apoptosis in some cancer cell lines [12,32,34], in the
present study the growth inhibition induced by three TK
inhibitors was mainly cytostatic. The apoptosis induced by
three TK inhibitors was observed in only one cell line (ZL34)
with higher drug concentration (10 mM). The failure to induce
apoptosis in two mesothelioma cell lines was probably
because most cancer cell lines secrete several autocrine
growth factors, some of which are likely to maintain survival
in the absence of serum [36]. In addition, in the present study
apoptosis was examined at only one time point (24 hours),
any transient increase in apoptosis may have gone unde-
tected. Other studies reported a similar observation that TK
inhibitor treatment leads to primarily cytostatic rather than
cytotoxic effects in malignant mesothelioma cells [21]. Sim-
ilar findings have also been observed in in vitro studies using
ovarian, breast, and colon cancer cell lines [12].
Another important finding in the present study was that all
three TK inhibitors inhibited TGF-a–induced chemotaxis and
production of MMP-9. It is widely accepted that cell migration
and enzymic degradation of extracellular matrix (ECM) play
an essential role in tumor invasion and metastasis [27]. Our
previous studies and unpublished results have shown that
mesothelioma cells migrate to different ECM components,
such as type IV collagen, and different growth factors,
including ligands of EGFR [23–26]. In the present study,
ZD1839, OSI-774, and CI-1033 inhibited TGF-a–induced
chemotaxis but failed to inhibit type IV collagen–induced
haptotaxis. This difference may be the fact that these two
motile processes are governed by a distinct signal transduc-
tion pathway [2]. Our previous studies have also shown that
mesothelioma cells express several members of the MMP
family and that different growth factors regulate production of
MMP-9 [28,29]. Furthermore, EGFR activation initiates com-
plex signaling cascades, which can result in various cellular
effects, including regulation of cell invasion and metastasis
by several downstream signaling mechanisms. For instance,
EGFR-phospholipase C-g signaling is required for enhanced
cell motility in prostate carcinoma [22]; phosphatidylinositol
Figure 4. (A–C) Inhibition of TGF-a– induced chemotaxis by TK inhibitors in malignant mesothelioma cells. Lower wells of Boyden chambers were filled with
TGF-a (12.5 ng/ml) diluted in serum-free RPMI supplemented with 1 mg/ml BSA. The membranes were coated on both sides with 10 g/ml of collagen type IV.
Mesothelioma cells (preincubated overnight with indicated concentrations of different drugs that remained with the cells throughout the assay) were placed in the
upper wells of Boyden chambers. The number of migrated cells is the mean ± SD of triplicates for each data point.
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Figure 5. (A–C) Inhibition of MMP-9 production by TK inhibitors in malignant mesothelioma cells. The gels show proteolytic activity in serum-free conditioned
medium in the presence or absence of different drugs and/or TGF-a. Bars summarize the relative activity of the area and intensity of MMP-9 and MMP-2, as
determined by image analysis, with 0 ng/ml of TGF-a and 0 M of drugs of MMP-9 band set as 1. Data shown are representative of three independent experiments.
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3-kinase/Akt signaling is involved in colorectal carcinoma cell
migration [10]; and mitogen-activated protein kinase/p21-
activated kinase 1 signaling mediated cell motility in skin
cancer cells [4]. Previous studies of metastases of bladder
carcinoma xenografts have shown that treatment of tumor-
bearing mice with anti-EGFR MAb 225 results in prevention
of metastases formation, accompanied by a decrease in
tumor production of MMP-9 [20]. In addition, the study of
metastases of murine hepatocellular carcinoma has also
shown that TK inhibitor ZD1839 inhibited EGFR-induced
chemotactic migration and production of active MMP-9
in vitro and introhepatic metastasis in vivo [30]. These
studies provide evidence that cellular activities potentiating
metastasis can be regulated by different EGFR downstream
signaling pathways. These studies and our present results
indicate that EGFR signaling plays an important role in tumor
metastasis and EGFR inhibitors are effective at inhibiting
tumor metastasis in vitro and in vivo.
Malignant mesothelioma is an asbestos-associated tu-
mor. Previous studies suggested that EGFR signaling may
be involved in asbestos-induced pathogenesis of malignant
mesothelioma. For instance, asbestos-transformed rat me-
sothelial cells express EGFR and TGF-a [44], and asbestos
fiber can induce the phosphorylation of EGFR, which
appears to correlate with the carcinogenicity of asbestos
fibers in rat pleural mesothelial cells [46]. A specific inhibitor
of EGFR, tyrphostin AG 1478, can significantly inhibit acti-
vator protein-1 DNA binding activity and EGFR phosphoryl-
ation after exposure of mesothelial cells to crocidolite, a
fibrous asbestos preparation [16]. In addition, a recent study
has demonstrated that TK inhibitor ZD1839 significantly
enhanced the antitumor activity of radiation in a mesotheli-
oma model [40]. Many other studies have also revealed a
potentiation of the antitumor effects of cytotoxic chemother-
apy agents by TK inhibitor ZD1839 in various human tumor
models [12]. Taken together, these studies strongly suggest
that EGFR signaling is involved in the pathogenesis of
malignant mesothelioma and the blockade of EGFR signal-
ing pathway may provide a potential therapeutic target for
treatment of patients with malignant mesothelioma.
In conclusion, the present study demonstrates that the
selective EGFR-TK inhibitors ZD1839 and OSI-774 and the
pan-EGFR family TK inhibitor CI-1033 are effective at inhib-
iting not only proliferation, but also migration and MMP-9
production of all three histologic types of mesothelioma cells.
Therefore, these three TK inhibitors can be considered as
new targets for further therapeutic interventions in patients
with malignant mesothelioma.
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